Could Vanda Pharmaceuticals Inc (NASDAQ:VNDA) Go Down After Its Newest Short Interest Report?

March 15, 2018 - By Ellis Scott

 Could Vanda Pharmaceuticals Inc (NASDAQ:VNDA) Go Down After Its Newest Short Interest Report?

Investors sentiment increased to 1.43 in 2017 Q3. Its up 0.26, from 1.17 in 2017Q2. It increased, as 12 investors sold Vanda Pharmaceuticals Inc. shares while 34 reduced holdings. 21 funds opened positions while 45 raised stakes. 38.89 million shares or 4.39% more from 37.25 million shares in 2017Q2 were reported.
California Employees Retirement Sys holds 0% of its portfolio in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) for 61,172 shares. Comml Bank Of Montreal Can has 0% invested in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA). Art Advsr Limited Company holds 59,900 shares. Baker Bros Advisors L P owns 423,884 shares or 0.06% of their US portfolio. Armistice Capital Ltd Liability Company holds 3.23% or 1.53 million shares in its portfolio. Strs Ohio invested in 44,100 shares. Rhumbline Advisers accumulated 0% or 51,321 shares. Principal Finance Group Inc, a Iowa-based fund reported 213,898 shares. Tiaa Cref Invest Mngmt Ltd Co accumulated 0.01% or 424,887 shares. Kistler holds 0% in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) or 200 shares. Prelude Management Llc invested in 1,523 shares or 0% of the stock. Cadence Cap Management Lc accumulated 62,606 shares. Moreover, State Board Of Administration Of Florida Retirement has 0% invested in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA). Ameriprise Financial holds 0% or 88,160 shares. Connecticut-based Great Point Prtnrs Ltd has invested 1.73% in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA).

Since January 2, 2018, it had 0 insider buys, and 8 selling transactions for $4.89 million activity. Kelly James Patrick also sold $159,712 worth of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) on Wednesday, February 28. $130,777 worth of stock was sold by Birznieks Gunther on Tuesday, January 2. 10,367 shares valued at $157,565 were sold by Gulino Richard L. on Tuesday, January 2.

The stock of Vanda Pharmaceuticals Inc (NASDAQ:VNDA) registered a decrease of 0.78% in short interest. VNDA’s total short interest was 1.97M shares in March as published by FINRA. Its down 0.78% from 1.98M shares, reported previously. With 593,300 shares average volume, it will take short sellers 3 days to cover their VNDA’s short positions. The short interest to Vanda Pharmaceuticals Inc’s float is 4.98%.

The stock decreased 2.48% or $0.5 during the last trading session, reaching $19.7. About 453,365 shares traded. Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) has risen 51.60% since March 15, 2017 and is uptrending. It has outperformed by 34.90% the S&P500.

Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system disorders. The company has market cap of $895.13 million. The company??s marketed products include HETLIOZ , a product for the treatment of non-24-hour sleep-wake disorder; and Fanapt (iloperidone), a product for the treatment of schizophrenia. It currently has negative earnings. The Company’s clinical development products include Tradipitant (VLY-686), a small molecule neurokinin-1 receptor antagonist that is under the clinical development for the treatment of chronic pruritus in atopic dermatitis and gastroparesis; Trichostatin A, a small molecule histone deacetylase inhibitor, which is in development for the treatment of hematologic malignancies; and AQW051, a Phase II alpha-7 nicotinic acetylcholine receptor partial agonist.

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Ratings Coverage

Among 8 analysts covering Vanda Pharmaceuticals (NASDAQ:VNDA), 8 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Vanda Pharmaceuticals had 24 analyst reports since September 2, 2015 according to SRatingsIntel. Oppenheimer maintained Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) on Sunday, November 12 with “Buy” rating. The firm earned “Buy” rating on Wednesday, February 28 by Seaport Global. The stock of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) earned “Buy” rating by Jefferies on Monday, September 4. Oppenheimer maintained the stock with “Buy” rating in Monday, January 8 report. JMP Securities maintained the shares of VNDA in report on Friday, August 26 with “Market Outperform” rating. As per Monday, October 30, the company rating was maintained by Oppenheimer. The rating was reinitiated by Jefferies on Thursday, October 6 with “Buy”. The company was maintained on Wednesday, September 2 by Piper Jaffray. Piper Jaffray maintained Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) on Thursday, August 3 with “Buy” rating. The stock of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) has “Buy” rating given on Wednesday, November 9 by Aegis Capital.

More notable recent Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) news were published by: which released: “Vanda Pharma shares decline as goal of itch drug study not reached” on September 13, 2017, also with their article: “Vanda Pharmaceuticals (VNDA) Reports Demonstrated Efficacy for HETLIOZ from …” published on March 05, 2018, published: “Vanda Pharmaceuticals Inc. Proposes Public Offering of Common Stock” on March 14, 2018. More interesting news about Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) were released by: and their article: “Vanda Pharmaceuticals Reports First Quarter 2017 Financial Results” published on May 02, 2017 as well as‘s news article titled: “Vanda Pharmaceuticals Reports Preliminary Fourth Quarter and Full Year 2017 …” with publication date: January 07, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: